Titlebook: Resistance to Targeted Therapies in Breast Cancer; Jenifer R. Prosperi Book 2017 Springer International Publishing AG 2017 Targeted Therap

Maudlin

書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer影響因子(影響力)




書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer影響因子(影響力)學(xué)科排名




書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer被引頻次




書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer被引頻次學(xué)科排名




書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer年度引用




書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer年度引用學(xué)科排名




書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer讀者反饋




書(shū)目名稱(chēng)Resistance to Targeted Therapies in Breast Cancer讀者反饋學(xué)科排名

Concerto

單片眼鏡

Resistance to HER2-Targeted Therapy,pressed in 20–25% of breast cancers and high expression is associated with poor clinical outcomes if not treated with an HER2-targeted drug. Although HER2 does not have a known extracellular ligand, HER2 is the preferred heterodimerization partner for the other HER-family receptors and HER2-containi

amputation

Endocrine Resistance and Breast Cancer Stem Cells: The Inflammatory Connection that Could Lead to Nstrogen receptor (ER) and will be treated with endocrine therapy, such as tamoxifen or aromatase inhibitors. Interfering with ER action via endocrine therapies has been a mainstay of breast cancer treatment for more than a century. But despite its proven success, the onset of endocrine resistance li

無(wú)孔

EGFR Resistance,ll growth by inhibiting epidermal growth factor receptors (EGFRs). Targeting the EGFR has been intensely pursued in the breast cancer, with mixed results and challenges with respect to treatment resistance emerging over time. The resistance to EGFR inhibitors is now well recognized due its high prev

incite

Targeting FGFR for the Treatment of Breast Cancer,f at least 5 distinct subtypes of the disease. Importantly, breast cancer subtyping can predict for tumor recurrence and drives the clinical application of endocrine and human epidermal growth factor receptor 2 (Her2)-targeted therapies. Recent studies have revealed that these subtypes of breast can

腐蝕

LOPE

Future Paradigm of Breast Cancer Resistance and Treatment,detecting the disease progression and relapse. Resistance to therapy is not only common but expected. Multidisciplinary joint efforts are required in making necessary progress with breast cancer treatment. With the recent advances in multiplex genotyping and high-throughput genomic sequencing techno

Customary

Book 2017ncer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy..

Orthodontics

Book 2017t ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy.